Biome signs landmark agreement to develop novel biological Intellectual Property laying the foundations for the next phase of growth
- Biome has executed an agreement with one of its key probiotic research and development partners, to develop multiple novel probiotic strains to be 100% owned by Biome
- Under this agreement development costs are capped at EUR €115,000 per strain
- The agreement includes manufacturing support to ferment the novel strains which Biome intends to commercialise
- Biome is finalising its strategic plan for the next 3 years, known as Biome Vision 27, which will be released to market in FY24 and will include IP Development as a key component
- Biome is sufficiently funded for FY24
